Cat. No.: HY-14768

Favipiravir

(Synonyms: T-705)

51 Cited Publications

Customer Review

Based on 51 publication(s) in Google Scholar

Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 259793-96-9
Formula: C₅H₄FN₃O₂
Molecular Weight:157.10

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Favipiravir Chemical Structure

CAS No.: 259793-96-9

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (51)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

RNA Polymerase

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	CC₅₀	>100 μM Compound: 6; T-705	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	>10 μM Compound: 6; T-705	Anti-influenza activity against Influenza A virus H3N2 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza A virus H3N2 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	>10 μM Compound: 6; T-705	Anti-influenza activity against Influenza B virus Victoria/2/87 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza B virus Victoria/2/87 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	>10 μM Compound: 6; T-705	Anti-influenza activity against Influenza B virus Yamagata/16/88 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza B virus Yamagata/16/88 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	8.29 μM Compound: 6; T-705	Anti-influenza activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	CC₅₀	>50 μM Compound: FPV	Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
MDCK	CC₅₀	>641 μM Compound: T-705	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 17194832]
MDCK	EC₅₀	11.5 μM Compound: T-705	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	12.1 μM Compound: T-705	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	2.6 μM Compound: T-705	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	4.5 μM Compound: T-705	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.19 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi	[PMID: 20350949]
MDCK	EC₅₀	0.38 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.45 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis	[PMID: 20350949]
MDCK	EC₅₀	0.57 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	[PMID: 20350949]
MDCK	EC₅₀	0.89 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days	[PMID: 20350949]
MDCK	EC₅₀	0.89 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco	[PMID: 20350949]
MDCK	EC₅₀	0.96 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af	[PMID: 20350949]
MDCK	EC₅₀	1.27 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after	[PMID: 20350949]
MDCK	EC₅₀	1.341 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral	[PMID: 20350949]
MDCK	EC₅₀	1.4 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	[PMID: 20350949]
MDCK	EC₅₀	1.4 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.46 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.53 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.59 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry	[PMID: 20350949]
MDCK	EC₅₀	1.59 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	[PMID: 20350949]
MDCK	EC₅₀	1.72 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	[PMID: 20350949]
MDCK	EC₅₀	1.85 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.97 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	[PMID: 20350949]
MDCK	EC₅₀	10.2 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	[PMID: 20350949]
MDCK	EC₅₀	2.23 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a	[PMID: 20350949]
MDCK	EC₅₀	2.48 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.55 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	[PMID: 20350949]
MDCK	EC₅₀	2.87 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	[PMID: 20350949]
MDCK	EC₅₀	2.93 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi	[PMID: 20350949]
MDCK	EC₅₀	2.93 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte	[PMID: 20350949]
MDCK	EC₅₀	22.48 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli	[PMID: 20350949]
MDCK	EC₅₀	3 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u	[PMID: 20350949]
MDCK	EC₅₀	3.25 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal	[PMID: 20350949]
MDCK	EC₅₀	3.38 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a	[PMID: 20350949]
MDCK	EC₅₀	3.63 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3.95 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	[PMID: 20350949]
MDCK	EC₅₀	4.01 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.08 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an	[PMID: 20350949]
MDCK	EC₅₀	4.14 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition	[PMID: 20350949]
MDCK	EC₅₀	4.2 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an	[PMID: 20350949]
MDCK	EC₅₀	4.46 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy	[PMID: 20350949]
MDCK	EC₅₀	4.52 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal	[PMID: 20350949]
MDCK	EC₅₀	4.7 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr	[PMID: 20350949]
MDCK	EC₅₀	4.9 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr	[PMID: 20350949]
MDCK	EC₅₀	5.03 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	[PMID: 20350949]
MDCK	EC₅₀	5.03 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	[PMID: 20350949]
MDCK	EC₅₀	5.22 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic	[PMID: 20350949]
MDCK	EC₅₀	5.22 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	[PMID: 20350949]
MDCK	EC₅₀	5.3 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.41 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi	[PMID: 20350949]
MDCK	EC₅₀	5.99 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole	[PMID: 20350949]
MDCK	EC₅₀	6.62 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re	[PMID: 20350949]
MDCK	CC₅₀	>100 μM Compound: T-705	Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.32 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.93 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.94 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	2.84 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	4.71 μM Compound: T-705	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	6.95 μM Compound: T-705	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	CC₅₀	>400 μM Compound: 1; T-705	Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay	[PMID: 27120583]
MDCK	EC₅₀	2.7 μM Compound: 1; T-705	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira	[PMID: 27120583]
MDCK	CC₅₀	>250 μM Compound: T-705	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	>250 μM Compound: T-705	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	>2000 μg/mL Compound: Favipiravir	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 35196598]
MDCK	CC₅₀	>1000 μM Compound: T-705	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability Cytotoxicity against dog MDCK cells assessed as reduction in cell viability	[PMID: 35729787]
MDCK	CC₅₀	>100 μM Compound: T-705	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36764470]
MDCK	CC₅₀	>1000 μM Compound: Favipiravir	Cytotoxicity against MDCK cells assessed as reduction in cell viability Cytotoxicity against MDCK cells assessed as reduction in cell viability	[PMID: 38283223]
MDCK	CC₅₀	>250 μM Compound: FPV	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
Vero	CC₅₀	>6257 μM Compound: T-705	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days	[PMID: 17606691]
Vero	CC₅₀	1114 μM Compound: T-705	Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay	[PMID: 17606691]
Vero	EC₅₀	5 μM Compound: T-705	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	6 μM Compound: T-705	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	6 μM Compound: T-705	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	CC₅₀	>6370 μM Compound: T-705	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	[PMID: 18955536]
Vero	EC₅₀	180 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	[PMID: 18955536]
Vero	EC₅₀	270 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay	[PMID: 18955536]
Vero	EC₅₀	270 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay	[PMID: 18955536]
Vero	EC₅₀	18.6 μg/mL Compound: Favipiravir	Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay	[PMID: 31431358]
Vero	EC₅₀	3.5 μg/mL Compound: 55	Antiviral activity against Zika virus MR766 infected in Vero cells assessed as reduction in viral replication by plaque reduction assay Antiviral activity against Zika virus MR766 infected in Vero cells assessed as reduction in viral replication by plaque reduction assay	[PMID: 33486200]
Vero	CC₅₀	>1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 33766766]
Vero	CC₅₀	>1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells infected with Zaire ebolavirus Cytotoxicity against African green monkey Vero cells infected with Zaire ebolavirus	[PMID: 36898483]
Vero	CC₅₀	>1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells infected with Marburgvirus Angola Cytotoxicity against African green monkey Vero cells infected with Marburgvirus Angola	[PMID: 36898483]
Vero	CC₅₀	>1000 μM Compound: 12	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 7 days by resazurin staining based analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 7 days by resazurin staining based analysis	[PMID: 38128296]
Vero C1008	CC₅₀	>400 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	[PMID: 32511912]
Vero C1008	CC₅₀	>400 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	CC₅₀	>400 μM Compound: T-705	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay	[PMID: 32771797]
Vero C1008	CC₅₀	>400 μM Compound: 4; FPV	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	IC₅₀	67 μM Compound: 22	Antiviral activity against EBOV infected in Vero E6 cells assessed as reduction in virus titer incubated for 5 days by immunofocus assay Antiviral activity against EBOV infected in Vero E6 cells assessed as reduction in virus titer incubated for 5 days by immunofocus assay	[PMID: 33352046]
Vero C1008	CC₅₀	>400 μM Compound: 55	Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay	[PMID: 33486200]
Vero C1008	EC₅₀	10.5 μg/mL Compound: 55	Antiviral activity against Ebolavirus infected in Vero E6 cells assessed as reduction in viral replication measured after 5 days by immunofocus assay Antiviral activity against Ebolavirus infected in Vero E6 cells assessed as reduction in viral replication measured after 5 days by immunofocus assay	[PMID: 33486200]
Vero C1008	EC₅₀	61.88 μM Compound: 55	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	CC₅₀	5.262 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 36708678]
Vero C1008	CC₅₀	>400 μM Compound: Favipiravir	Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36965227]
Vero C1008	CC₅₀	5262 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 37329713]
Vero C1008	CC₅₀	>1000 μM Compound: Favipiravir	Cytotoxicity against african green monkey Vero E6 cells Cytotoxicity against african green monkey Vero E6 cells	[PMID: 39248591]

In Vitro

Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC₅₀>1 mM. The IC₅₀ for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis^[1]. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC₅₀: 250±11 μM) and MNV RNA synthesis in cell culture (EC₅₀:124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 259793-96-9
Appearance Solid
Molecular Weight 157.10
Formula C₅H₄FN₃O₂
Color White to light yellow
SMILES

O=C(N)C1=NC(F)=CNC1=O
Synonyms

T-705
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (51)

All Microbiological AssayOthersCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Nat Commun

Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice. [Abstract]

2026 Feb 19. PMID: 41714318
NPJ Digit Med

Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]

2025 Nov 21;8(1):712. PMID: 41272280
Acta Pharm Sin B

A novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA-PB1 interactions and modulating host macrophage inflammation. [Abstract]

2025 Aug;15(8):4156-4173. PMID: 40893672
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Int J Biol Sci

NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. [Abstract]

2020 Oct 16;16(16):3100-3115. PMID: 33162818
Emerg Microbes Infect

Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]

2025 Dec;14(1):2564308. PMID: 41069204

Favipiravir purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]

Drug susceptibility profiles of Favipiravir were assessed using a viral yield reduction assay in MDCK cells. Cells were infected with IDV and IAV (MOI = 0.1), followed by removal of the virus inoculum and treatment with the drugs. Supernatants from IDV and Influenza A virus (IAV) infections were collected at 72 and 48 hpi, respectively, and viral titres were determined in MDCK cells. Antiviral activity (%) was calculated relative to virus-free and drug-free controls.
Cell Chem Biol

Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]

2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599
Eur J Med Chem

Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization. [Abstract]

2024 Aug 3:277:116737. PMID: 39153334
Bioeng Transl Med

IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. [Abstract]

2020 Dec 1;6(1):e10196. PMID: 33532594
Int J Mol Sci

Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2. [Abstract]

2023 Feb 2;24(3):2849. PMID: 36769193
Front Pharmacol

An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection. [Abstract]

2019 Oct 16;10:1203. PMID: 31680975

Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

Vero E6 cells in 12-well plates were infected with HTNV at an FFU of 30/well (T-705; Favipiravir) and incubated with a CMC overlay supplemented with serial two-fold dilutions of inhibitors. At 5 dpi, the foci were counted and calculated. These experiments were performed independently at least three times with similar results.

Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

Inhibitory effects of T-705 (Favipiravir) and BXA (Baloxavir) on HTNV replication, as measured by FFA. Vero E6 cells were infected with HTNV at an FFU of 30/well (T-705) or 50/well (BXA) and treated with serial two-fold dilutions of inhibitors. The foci were counted 5 dpi. Each point represents the mean and SD of three independent experiments.

Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

Cell viability as a percentage of the control cell (treated with DMSO for T-705 or PBS for BXA) viability in uninfected Vero E6 cells incubated for 72 h post-T-705 (Favipiravir)/BXA (Baloxavir) treatment. Each point represents the mean and SD of three independent experiments.
mBio

GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. [Abstract]

2020 Aug 20;11(4):e01833-20. PMID: 32820005
Bioorg Chem

Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics. [Abstract]

2024 Mar:144:107139. PMID: 38262086
Antimicrob Agents Chemother

Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]

2020 Jun 23;64(7):e00222-20. PMID: 32312780
Antimicrob Agents Chemother

Antiviral Candidates for Treating Hepatitis E Virus Infection. [Abstract]

2019 May 24;63(6). pii: e00003-19. PMID: 30885901
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
Virol Sin

Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]

2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248
Antiviral Res

Identification of a macrocyclic compound targeting the lassa virus polymerase. [Abstract]

2024 Jun 4:105923. PMID: 38844175
Antiviral Res

Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection. [Abstract]

2023 Oct:218:105703. PMID: 37611878
Antiviral Res

Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. [Abstract]

2020 Dec;184:104955. PMID: 33091434
Antiviral Res

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]

2020 Jun;178:104786. PMID: 32251767
Antiviral Res

Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. [Abstract]

2018 Jan:149:34-40. PMID: 29126899
Sci Rep

Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. [Abstract]

2021 Sep 8;11(1):17810. PMID: 34497279
J Virol

Enterovirus 71 2A Protease Inhibits P-Body Formation To Promote Viral RNA Synthesis. [Abstract]

2021 Sep 9;95(19):e0092221. PMID: 34287048
J Antimicrob Chemother

Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model. [Abstract]

2025 Oct 3;80(10):2807-2813. PMID: 40888812
Viruses

Antiviral Activity of Selective Estrogen Receptor Modulators against Severe Fever with Thrombocytopenia Syndrome Virus In Vitro and In Vivo. [Abstract]

2024 Aug 20;16(8):1332. PMID: 39205306
Viruses

Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses. [Abstract]

2023 Jan 15;15(1):244. PMID: 36680284
Viruses

In Silico Structure-Based Design of Antiviral Peptides Targeting the Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Gn. [Abstract]

2021 Oct 11;13(10):2047. PMID: 34696477
Viruses

Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. [Abstract]

2021 Jun 28;13(7):1255. PMID: 34203149
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Viruses

Potential Therapeutic Agents for Feline Calicivirus Infection. [Abstract]

2018 Aug 16;10(8). pii: E433. PMID: 30115859
Vaccine

Re-evaluating the effect of Favipiravir treatment on rabies virus infection. [Abstract]

2019 Aug 2;37(33):4686-4693. PMID: 29132993
ChemMedChem

Streamlined Synthesis and Structure-Activity Relationship Analysis of 2-Amidothiophene-3-Carboxamides Targeting Influenza Polymerase PA-PB1 Heterodimerization. [Abstract]

2026 May 27;21(10):e70314. PMID: 42174748
Pathogens

2026 Feb;15(2):169.
BMC Vet Res

Antiviral efficacy of favipiravir against canine distemper virus infection in vitro. [Abstract]

2019 Sep 2;15(1):316. PMID: 31477101

Favipiravir purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]

Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. Viral replications in cells were detected by IFA and the mean fluorescence percentages (a, c, e, g) were calculated

Favipiravir purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]

Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. The virus titers in supernatant (b, d, f, h) were determined and compared with the viral titers in mock group. All e
Virology

BCX4430 inhibits the replication of rabies virus by suppressing mTOR-dependent autophagy invitro. [Abstract]

2023 Aug:585:21-31. PMID: 37267717
Virology

Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. [Abstract]

2020 Jun;545:1-9. PMID: 32174453
Virology

The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir. [Abstract]

2019 Oct:536:58-67. PMID: 31400550
Biopharm Drug Dispos

Favipiravir biotransformation in liver cytosol: Species and sex differences in humans, monkeys, rats, and mice. [Abstract]

2021 May;42(5):218-225. PMID: 33754379
Anal Sci

Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19. [Abstract]

2021 Sep 10;37(9):1301-1304. PMID: 33612558
J Virol Methods

Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin. [Abstract]

2021 Dec:298:114283. PMID: 34534610
J Infect Chemother

Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study. [Abstract]

2022 Jan;28(1):73-77. PMID: 34711508
Res Sq

2025 Dec 18.
Auburn University

2025 Aug 9.
bioRxiv

Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo. [Abstract]

2025 Jan 25:2025.01.24.633564. PMID: 39896535
SSRN

2023 Dec 20.
Research Square Preprint

2023 Oct 12.
Research Square Preprint

2021 Oct.
Research Square Preprint

2021 Apr.
Universidade de São Paulo

2020 Sep.
bioRxiv

2020 Apr.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (636.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 6.25 mg/mL (39.78 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.3654 mL

31.8269 mL

63.6537 mL

5 mM

1.2731 mL

6.3654 mL

12.7307 mL

10 mM

0.6365 mL

3.1827 mL

6.3654 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline